7-93999179-AG-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_005868.6(BET1):c.134delC(p.Ala45fs) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000228 in 1,611,196 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00024 ( 0 hom. )
Consequence
BET1
NM_005868.6 frameshift
NM_005868.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.72
Genes affected
BET1 (HGNC:14562): (Bet1 golgi vesicular membrane trafficking protein) This gene encodes a golgi-associated membrane protein that participates in vesicular transport from the endoplasmic reticulum (ER) to the Golgi complex. The encoded protein functions as a soluble N-ethylaleimide-sensitive factor attachment protein receptor and may be involved in the docking of ER-derived vesicles with the cis-Golgi membrane. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BET1 | NM_005868.6 | c.134delC | p.Ala45fs | frameshift_variant | 2/4 | ENST00000222547.8 | NP_005859.1 | |
BET1 | NM_001317739.2 | c.134delC | p.Ala45fs | frameshift_variant | 2/5 | NP_001304668.1 | ||
BET1 | NR_133908.2 | n.273delC | non_coding_transcript_exon_variant | 2/7 | ||||
BET1 | NR_133909.2 | n.273delC | non_coding_transcript_exon_variant | 2/5 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152234Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
16
AN:
152234
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000108 AC: 27AN: 250582Hom.: 0 AF XY: 0.0000517 AC XY: 7AN XY: 135502
GnomAD3 exomes
AF:
AC:
27
AN:
250582
Hom.:
AF XY:
AC XY:
7
AN XY:
135502
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000241 AC: 352AN: 1458962Hom.: 0 Cov.: 30 AF XY: 0.000231 AC XY: 168AN XY: 725786
GnomAD4 exome
AF:
AC:
352
AN:
1458962
Hom.:
Cov.:
30
AF XY:
AC XY:
168
AN XY:
725786
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000105 AC: 16AN: 152234Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74378
GnomAD4 genome
AF:
AC:
16
AN:
152234
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
74378
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Muscular dystrophy, congenital, with rapid progression Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 06, 2024 | - - |
Seizure;C0240421:Progressive muscle weakness Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Feb 25, 2019 | The heterozygous p.Ala45ValfsTer2 variant in BET1 was identified by our study in trans with a VUS missense variant in one individual with progressive muscular weakness and seizures. This variant has been identified in 0.018% (24/128800) of European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs541754296). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at position 45 and leads to a premature termination codon 2 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. While this alteration is then predicted to lead to a truncated or absent protein, this variant was detectable in the muscle RNA. However, western blot analysis showed reduced to absent BET1 in patient fibroblasts compared to controls. Of note, loss of function of the BET1 gene in autosomal dominant disease has not yet been established based on the criteria laid out in Tayoun, 2018 (PMID: 30192042). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at